Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib in ALK-Positive NSCLC Patients With Brain Metastases
NCT03753685Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Apr 2019
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Started Apr 2019; status: active, not recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03753685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03753685.